NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS
January 2, 2025
NeuroSense Therapeutics Ltd, a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, announced that it has entered into a binding term sheet